Drawing on a massive real-world dataset, DeLorean AI has released new evidence that its cardio ai platform can transform cardiovascular care and economics in the US healthcare system.
New white paper highlights predictive performance and cost impact
In a new white paper published from Palm Beach on Dec. 17, 2025, DeLorean AI details how its Cardio AI system identifies patients likely to progress to heart failure long before symptoms emerge. The analysis is based on 12 million patient records spanning longitudinal EHR and claims data.
The company reports that its models achieve 87% sensitivity in predicting progression toward heart failure. Moreover, the study shows that using these predictions to guide earlier intervention can reduce avoidable care costs by $250,000–$350,000 per patient per year, creating a powerful economic case for predictive care.
“Value-based care is under enormous pressure right now, as we have seen with Optum renegotiating many of its contracts,” said Dr. Severence MacLaughlin, CEO and Founder of DeLorean AI. However, he argued that payment models could be stabilized if payers, providers, and agencies such as CMS and HHS had advance visibility into patient deterioration.
“Predictive AI is the missing infrastructure that allows value-based care to actually work,” Dr. MacLaughlin said, positioning the technology as a foundation for sustainable reimbursement structures.
Cardiovascular burden and the cost of late-stage heart failure
Cardiovascular disease remains the single largest driver of medical spending in the United States, with annual costs reaching $417.9 billion and contributing to more than 941,000 deaths each year. Moreover, heart failure is among the most expensive manifestations of this burden when care begins only at the point of diagnosis.
According to the white paper, heart failure alone can exceed $350,000 per patient in the year of diagnosis. That said, DeLorean AI emphasizes that heart failure often follows a predictable and preventable trajectory when proactive management begins in earlier stages such as hypertension or ischemic heart disease.
Model performance and clinical insight
DeLorean AI’s models scan longitudinal data to reveal subtle patterns of deterioration well before conventional clinical thresholds are crossed. The study lists several key performance metrics that, according to the company, match or surpass leading peer-reviewed cardiovascular machine-learning research while using a significantly larger dataset.
First, the system accurately detects early deterioration from hypertension or ischemic heart disease toward heart failure with 87% sensitivity. Additionally, it offers predictive insight into whether a patient’s condition is likely to improve, worsen, or remain stable, with 85–87% accuracy reported in the white paper.
Third, the platform can predict an acute heart failure hospitalization as far as 90 days in advance, enabling clinicians to act before a crisis occurs. Moreover, it generates Next Best Actions for licensed professionals, helping avert adverse cardiac events, reduce hospitalizations, and lower costs.
DeLorean AI describes this as a clinically validated, transparent approach that delivers actionable intelligence rather than black-box scores. These metrics, the company notes, are designed to support scalable ai risk stratification in real-world health systems.
From prediction to intervention: shifting care upstream
“Predictive and Interventive AI for prevention is now possible at scale,” Dr. MacLaughlin said, highlighting the shift from reactive to proactive cardiology. By allowing clinicians to see risk trajectories weeks or months ahead, the platform aims to keep patients out of intensive, high-cost care settings.
He explained that clinicians can now visualize risk at two, four, and eight weeks into the future. Furthermore, this forward-looking view helps hospitals stay ahead of deterioration and deliver care that is more precise, proactive, and personalized for each individual.
The white paper also addresses a core clinical question: how to prevent heart failure before it materializes in the first place. DeLorean AI argues that scalable prediction, coupled with guideline-based interventions, is essential to moving care into pre-event disease stages where outcomes are more controllable.
Cardio AI integration and workflow design
Cardio AI is designed to integrate with any electronic health record, maintaining providers at the center of decision-making. This broad ehr ai integration approach is intended to minimize disruption while embedding predictive insights directly into everyday clinical workflows.
Within the EHR, the platform flags patients who may be trending toward cardiac complications based on subtle changes in their data. Moreover, it identifies deviations from ACC/AHA guideline-recommended therapies, surfacing opportunities for clinicians to optimize management before serious events occur.
The system then presents patient-specific next-best actions rooted in evidence-based medicine, supporting primary care physicians and cardiologists with accessible, easy-to-interpret intelligence. That said, DeLorean AI stresses that clinicians retain full control, with the software acting as an adjunct rather than a replacement.
Economic impact: reducing preventable cardiac costs
The white paper quantifies how predictive and preventative care can reduce healthcare costs for health systems, insurers, and patients. Managing individuals in pre-event stages such as hypertension (I-10) or chronic ischemic heart disease (I-25) can lower cardiac claims by $60,000–$70,000 per patient annually, according to the analysis.
Preventing heart failure altogether delivers even larger savings, with estimated reductions of $250,000–$350,000 per patient each year. Moreover, with more than three million Americans currently at elevated cardiac risk, the paper argues that predictive intervention represents a pathway to billions of dollars in avoidable spending nationwide.
These savings are closely linked to the broader shift toward value based care models, where providers are rewarded for outcomes rather than volume. DeLorean AI positions its technology as a critical enabler of that transition, giving stakeholders the data needed to intervene earlier and avoid expensive complications.
Human-centric AI and ethical design
“Technology should amplify human expertise, not replace it,” Dr. MacLaughlin said, underscoring the company’s stance on the role of AI in medicine. Furthermore, he framed the platform as a way to give clinicians greater clarity and confidence when making high-stakes decisions for complex patients.
According to DeLorean AI, the system helps clinicians intervene earlier, reduce preventable complications, and improve outcomes across entire populations. However, the company emphasizes that its algorithms are built to support medical judgment rather than dictate treatment choices, in line with ethical AI principles.
DeLorean AI’s approach centers on transparency, rigorous clinical validation, and an explicit commitment to ethical development. The platform is built, the company says, for real hospitals, real providers, and real patients, offering precision without overpromising and innovation grounded in medical science.
Company background and broader disease focus
Based in Palm Beach, Florida, DeLorean AI is a healthtech company focused on predictive artificial intelligence for chronic and acute disease detection. The firm was founded by Dr. Severence MacLaughlin, who has positioned the business at the intersection of clinical medicine, data science, and operational transformation.
The company’s platform addresses multiple high-impact disease areas, including cardiovascular disease, chronic kidney disease, end stage renal disease, cardiovascular disease diabetes, COPD, and depression. Moreover, DeLorean AI reports having seven patents in process and a proprietary model trained on more than 80 million patient records, supporting real-time risk assessment at scale.
The solution delivers real-time risk stratification, suggested clinical actions, and future-state predictions designed to lower costs and extend lives. As DeLorean AI expands from B2B partnerships into direct-to-patient engagement, the company aims to redefine proactive, data-driven healthcare for both providers and individuals.
With the publication of its new cardiovascular white paper, DeLorean AI positions the cardio ai platform as a pivotal tool for predicting heart failure, guiding earlier intervention, and reshaping the economics of chronic cardiac care.
Source: https://en.cryptonomist.ch/2025/12/17/cardio-ai-platform/
